Sanofi Shares Fall on Mixed Lung Disease Drug Results
Itepekimab, a medicine that is being jointly developed by Sanofi and Regeneron, is being tested as a treatment for chronic obstructive pulmonary disease in former smokers. Two late stage trials showed contrasting results, Sanofi said Friday, with one showing a reduction in worsening of the condition — called exacerbations — of 27%. The other trial didn't show the same benefit despite having shown it earlier in the study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Danish Economy Bounces Back to Growth Led by Drugmakers
Denmark 's economy rebounded in the second quarter, as the strength of the broader pharmaceuticals industry helped to outweigh the impact of weaker sales of Novo Nordisk A/S's blockbuster weight-loss drugs. Gross domestic product, adjusted for seasonal swings, rose 1.3% from the previous three months, when it contracted 1.3%, Statistics Denmark said on Wednesday in a preliminary reading. The growth in the second quarter was driven by a bounce-back among drugmakers, with increased oil extraction also contributing, the statistics agency said.
Yahoo
an hour ago
- Yahoo
Eli Lilly to hike U.K. Mounjaro Price 170% after Trump push
Eli Lilly is raising the price of the weight loss drug Mounjaro in the U.K., after President Donald Trump ramped up pressure on drugmakers to lower U.S. prices and raise them abroad. The price of the drug is expected to rise by up to 170% in September, increasing the cost of a monthly supply at the highest dose from £122 ($165) to £330 ($447). The company said it had agreed with the British government to raise prices while 'maintaining access' for patients covered by the U.K.'s National Health Service. Last month, Trump wrote to 17 of the world's biggest drugmakers , including Eli Lilly, Novo Nordisk, and Pfizer, demanding they slash prices for U.S. consumers as part of his 'most favored nation' policy. The scheme aims to bring down drug prices by tying charges in the U.S. to lower ones abroad. Eli Lilly said Thursday that it has 'intensified efforts to align prices across developed countries, especially in Europe'. 'We are continuing to work with certain governments and expect to make any necessary pricing adjustments by September 1, while providing continued access for patients,' it said. Prescription drug prices in the U.S. are often two to three times higher on average than those in other developed nations, according to the nonprofit Commonwealth Fund. The list price for a month's supply of Mounjaro in the U.S. is $1,079.77 before insurance. Eli Lilly added that it supports Trump's goal of keeping the U.S. the 'world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries.' 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,' it said. Trump wrote in July that he would 'deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices' if companies did not comply with his demands, saying other countries had been 'freeloading on U.S. innovation'. Meanwhile, the pharmaceutical industry is bracing for planned U.S. tariffs of medicines imported into the country. Eli Lilly said Thursday that it opposes the tariffs, saying they will raise costs and limit access to drugs. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Missouri Department of Health launches digital access for immunizations
KANSAS CITY, Mo. — Missourians can now digitally access and share their immunization records. According to the Missouri Department of Health and Senior Services (DHSS), people in Missouri can review, download and share their immunization records through a mobile app called Docket and their web platform. The service expands digital access for school, travel, health and personal use. Missourians can use Docket to access personal and family immunization records on file with the Missouri Immunization Registry. Depending on individual providers' practices, it is possible for someone not to see all of their vaccinations in this system. How to get a spot at Patrick Mahomes, Travis Kelce's new steakhouse 1587 Prime Docket also allows residents to do the following: View, download and share their personal immunization history. Access records for children or individuals for whom they are a parent, legal guardian or authorized representative. Share official immunization documentation with schools, camps, health providers and travel officials. According to DHSS, immunization rates for Missouri kindergartners has declined. These were following rates for the 2024-25 school year: DTaP: 90.0% Hep B: 92.7% IPV/Polio: 90.7% MMR: 90.0% Varicella: 89.4% For more information about Docket and immunizations, you can click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
